Page last updated: 2024-11-01

nevirapine and Viremia

nevirapine has been researched along with Viremia in 24 studies

Nevirapine: A potent, non-nucleoside reverse transcriptase inhibitor used in combination with nucleoside analogues for treatment of HIV INFECTIONS and AIDS.
nevirapine : A dipyridodiazepine that is 5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepine which is substituted by methyl, oxo, and cyclopropyl groups at positions 4, 6, and 11, respectively. A non-nucleoside reverse transcriptase inhibitor with activity against HIV-1, it is used in combination with other antiretrovirals for the treatment of HIV infection.

Viremia: The presence of viruses in the blood.

Research Excerpts

ExcerptRelevanceReference
"Switching subjects with persistently undetectable HIV-1 viremia under antiretroviral treatment (ART) to once-daily tenofovir/emtricitabine (or lamivudine) + nevirapine is a cost-effective and well-tolerated strategy."7.81Effectiveness of a Treatment Switch to Nevirapine plus Tenofovir and Emtricitabine (or Lamivudine) in Adults with HIV-1 Suppressed Viremia. ( Bravo, I; Clotet, B; Llibre, JM; Martin-Iguacel, R; Ornelas, A; Paredes, R; Puig, J; Santos, JR, 2015)
"To determine whether residual plasma viremia in HIV(+) patients on nevirapine-including antiretroviral therapy (ART) is related to anti-HIV cellular immune responses, a case-control study was conducted comparing residual viremia in patients with detectable and undetectable Gag-specific T-cell responses."7.80Residual viremia in patients on antiretroviral therapy incorporating nevirapine is not associated with the gag-specific cellular immune response. ( Allavena, C; Billaud, E; Ferré, V; McIlroy, D; Raffi, F; Rodallec, A, 2014)
"Among HIV-infected children previously exposed to nevirapine, switching to nevirapine-based therapy after achieving viral suppression with a ritonavir-boosted lopinavir regimen resulted in lower rates of viremia greater than 50 copies/mL than maintaining the primary ritonavir-boosted lopinavir regimen."5.14Reuse of nevirapine in exposed HIV-infected children after protease inhibitor-based viral suppression: a randomized controlled trial. ( Abrams, EJ; Coovadia, A; Hu, CC; Hunt, G; Kuhn, L; Martens, L; Meyers, T; Morris, L; Sherman, G; Stehlau, R; Tsai, WY, 2010)
"All HIV-infected patients receiving a stable PI/r-based antiretroviral regimen, with persistently suppressed viremia, naïve to non-nucleoside analogues and to integrase strand transfer inhibitors, with mixed hyperlipidaemia, and who underwent a switch from PI/r to nevirapine (Group A) or raltegravir (Group B) or who started rosuvastatin at 10 mg daily (group C) with unchanged antiretroviral regimen were enrolled into the study."3.85Substitution of nevirapine or raltegravir for protease inhibitor vs. rosuvastatin treatment for the management of dyslipidaemia in HIV-infected patients on stable antiretroviral therapy (Nevrast study). ( Bon, I; Borderi, M; Bussini, L; Calza, L; Colangeli, V; Magistrelli, E; Re, MC; Viale, P, 2017)
" We assessed the relationship between plasma lopinavir or nevirapine concentrations and the risk of subsequent viremia in children initially suppressed on antiretroviral therapy."3.83Effect of Lopinavir and Nevirapine Concentrations on Viral Outcomes in Protease Inhibitor-experienced HIV-infected Children. ( Abrams, EJ; Castel, S; Coovadia, A; Kuhn, L; Maartens, G; McIlleron, H; Moholisa, RR; Patel, F; Pinillos, F; Schomaker, M; Strehlau, R; Wiesner, L, 2016)
"To determine whether residual plasma viremia in HIV(+) patients on nevirapine-including antiretroviral therapy (ART) is related to anti-HIV cellular immune responses, a case-control study was conducted comparing residual viremia in patients with detectable and undetectable Gag-specific T-cell responses."3.80Residual viremia in patients on antiretroviral therapy incorporating nevirapine is not associated with the gag-specific cellular immune response. ( Allavena, C; Billaud, E; Ferré, V; McIlroy, D; Raffi, F; Rodallec, A, 2014)
"To compare the level of HIV-1 residual viremia, defined by a viral load below 50 copies/ml in patients receiving a tenofovir/emtricitabine and nevirapine (NVP) or efavirenz (EFV)-containing regimen."3.77Higher efficacy of nevirapine than efavirenz to achieve HIV-1 plasma viral load below 1 copy/ml. ( Calvez, V; Flandre, P; Fourati, S; Girard, PM; Haïm-Boukobza, S; Katlama, C; Lavignon, M; Marcelin, AG; Morand-Joubert, L; Sayon, S; Simon, A; Valin, N, 2011)
"Nevirapine resistance after failed prophylaxis to prevent mother-to-child human immunodeficiency virus (HIV) transmission can compromise subsequent nevirapine-based highly active antiretroviral therapy (HAART)."3.77Induction therapy with protease-inhibitors modifies the effect of nevirapine resistance on virologic response to nevirapine-based HAART in children. ( Abrams, EJ; Chen, YH; Coovadia, A; Kuhn, L; Meyers, T; Moorthy, A; Persaud, D; Sherman, G; Strehlau, R; Tsai, WY, 2011)
"To describe the experience of four London HIV centres prescribing nevirapine (NVP) to HIV-1 infected pregnant women with respect to immunological and virological response, tolerability and pregnancy outcome."3.71Experience of nevirapine use in a London cohort of HIV-infected pregnant women. ( de Ruiter, A; Easterbrook, P; Edwards, SG; Hay, P; Larbalestier, N; Taylor, GP; Welch, J, 2001)
"Disease progression was particularly rapid, 85% infants meeting WHO criteria for ART within 6 months."2.73High frequency of rapid immunological progression in African infants infected in the era of perinatal HIV prophylaxis. ( Blanckenberg, N; Goulder, P; Kiepiela, P; McCarthy, N; Mkhwanazi, N; Mphatswe, W; Prendergast, A; Thobakgale, C; Tudor-Williams, G; Walker, BD, 2007)
" Overall, in 12 patients treated with hydroxyurea, 33 adverse events were reported versus 19 reported for 12 patients who did not receive hydroxyurea (p <."2.70Higher rate of toxicity with no increased efficacy when hydroxyurea is added to a regimen of stavudine plus didanosine and nevirapine in primary HIV infection. ( Cahn, P; Federico, A; Kijak, G; Montaner, JS; Ochoa, C; Perez, H; Salomon, H; Zala, C, 2002)
"Nevirapine was rapidly absorbed, but the time to peak plasma concentrations increased with higher doses."2.68Pharmacokinetics, safety, and activity of nevirapine in human immunodeficiency virus type 1-infected children. ( Bryson, Y; Cort, S; Lamson, M; Luzuriaga, K; McSherry, G; Robinson, J; Scott, G; Stechenberg, B; Sullivan, JL, 1996)
"Nevirapine was added to the drug regiment of eight children with HIV infection treated with the combination of zidovudine and didanosine who had increasing levels of serum p24 antigen."1.29Comparison of virus burden in blood and sequential lymph node biopsy specimens from children infected with human immunodeficiency virus. ( Anderson, B; Farley, M; Fox, C; Luzuriaga, K; Mueller, BU; Pizzo, PA; Schwartzentruber, DJ; Sei, S; Sullivan, JL; Tudor-Williams, G; Venzon, DJ, 1996)

Research

Studies (24)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's5 (20.83)18.2507
2000's7 (29.17)29.6817
2010's11 (45.83)24.3611
2020's1 (4.17)2.80

Authors

AuthorsStudies
Bhattacharya, D1
Guo, R1
Tseng, CH1
Emel, L1
Sun, R1
Chiu, SH1
Stranix-Chibanda, L1
Chipato, T1
Mohtashemi, NZ1
Kintu, K1
Manji, KP1
Moodley, D1
Thio, CL1
Maldonado, Y1
Currier, JS1
Calza, L1
Magistrelli, E1
Colangeli, V1
Borderi, M1
Bussini, L1
Bon, I1
Re, MC1
Viale, P1
Allavena, C2
Rodallec, A2
Sécher, S1
Reliquet, V1
Baffoin, S1
André-Garnier, E1
Billaud, E2
Raffi, F2
Ferré, V2
McIlroy, D1
Gupta, RK1
Goodall, RL1
Ranopa, M1
Kityo, C1
Munderi, P1
Lyagoba, F1
Mugarura, L1
Gilks, CF1
Kaleebu, P1
Pillay, D1
Ngemu, EK1
Khayeka-Wandabwa, C1
Kweka, EJ1
Choge, JK1
Anino, E1
Oyoo-Okoth, E1
Shearer, K1
Brennan, AT1
Maskew, M1
Long, L1
Berhanu, R1
Sanne, I1
Fox, MP1
Llibre, JM1
Bravo, I1
Ornelas, A1
Santos, JR1
Puig, J1
Martin-Iguacel, R1
Paredes, R1
Clotet, B1
Moholisa, RR1
Schomaker, M1
Kuhn, L3
Castel, S1
Wiesner, L1
Coovadia, A3
Strehlau, R2
Patel, F1
Pinillos, F1
Abrams, EJ3
Maartens, G1
McIlleron, H1
Stehlau, R1
Meyers, T2
Martens, L1
Sherman, G2
Hunt, G1
Hu, CC1
Tsai, WY2
Morris, L1
Haïm-Boukobza, S1
Morand-Joubert, L1
Flandre, P1
Valin, N1
Fourati, S1
Sayon, S1
Lavignon, M1
Simon, A1
Girard, PM1
Katlama, C1
Calvez, V2
Marcelin, AG2
Moorthy, A1
Chen, YH1
Persaud, D1
Weissbrich, B1
Langmann, P1
Schubert, J1
Jassoy, C1
Klinker, H1
Gianotti, N1
Boeri, E1
Maillard, M1
Serra, G1
Ratti, D1
Gallotta, G1
Vacchini, D1
Tremolada, Y1
Castagna, A1
Martinez, V1
Morini, JP1
Deleuze, J1
Krivine, A1
Gorin, I1
Yerly, S1
Perrin, L1
Peytavin, G1
Dupin, N1
Jakobsen, MR1
Tolstrup, M1
Bertelsen, L1
Laursen, A1
Obel, N1
Ostergaard, L1
Mohey, R1
Mphatswe, W1
Blanckenberg, N1
Tudor-Williams, G2
Prendergast, A1
Thobakgale, C1
Mkhwanazi, N1
McCarthy, N1
Walker, BD1
Kiepiela, P1
Goulder, P1
Cohen, J1
Mueller, BU1
Sei, S1
Anderson, B1
Luzuriaga, K2
Farley, M1
Venzon, DJ1
Schwartzentruber, DJ1
Fox, C1
Sullivan, JL2
Pizzo, PA1
Bryson, Y1
McSherry, G1
Robinson, J1
Stechenberg, B1
Scott, G1
Lamson, M1
Cort, S1
de Jong, MD1
de Boer, RJ1
de Wolf, F1
Foudraine, NA1
Boucher, CA1
Goudsmit, J1
Lange, JM1
James, JS1
Edwards, SG1
Larbalestier, N1
Hay, P1
de Ruiter, A1
Welch, J1
Taylor, GP1
Easterbrook, P1
Zala, C1
Salomon, H1
Ochoa, C1
Kijak, G1
Federico, A1
Perez, H1
Montaner, JS1
Cahn, P1

Clinical Trials (5)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase III Trial to Determine the Efficacy and Safety of an Extended Regimen of Nevirapine in Infants Born to HIV-Infected Women to Prevent Vertical HIV Transmission During Breastfeeding[NCT00074412]Phase 32,026 participants (Actual)Interventional2007-01-31Completed
Clinical Relevance of Nevirapine Resistance[NCT00117728]Phase 3250 participants (Anticipated)Interventional2005-04-30Recruiting
A Pharmacokinetics Study Comparing Lopinavir Plasma Exposure When Given as Lopinavir/Ritonavir (1:1) in the Presence of Rifampicin and Lopinavir/Ritonavir (4:1) Without Rifampicin in HIV and TB Co-infected Children in South Africa.[NCT02348177]Phase 496 participants (Actual)Interventional2013-01-31Completed
Pharmacokinetics, Safety, Tolerance, and Activity of Nevirapine (BI-RG-587) Alone and in Combination With AZT in Mildly to Moderately Symptomatic HIV-1 Infected Children[NCT00001111]35 participants InterventionalCompleted
A Pilot Pharmacokinetic Phase I Evaluation of BI-RG-587 in HIV-Infected Children[NCT00000634]6 participants InterventionalCompleted
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Frequency and Severity of Adverse Reactions Among Participating Infants

For those infants who were randomized at 6 weeks and who initiated study drug we looked at the frequency and severity of adverse reactions through 18 months of study. The severity of all AEs was graded according to the DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events. The term severity is described as the intensity grade or level for specific event (i.e. mild, moderate, severe, or life-threatening). Severity is not the same as seriousness. (NCT00074412)
Timeframe: 6 weeks through 18 months

,
InterventionNumber of Adverse Events (Number)
DeathLife-ThreateningSevereModerateMild
Nevirapine2687375694832
Placebo3087332677838

HIV Infection in Infants Determined to be HIV Uninfected at 6 Weeks Enrolled in Each Arm of the Study

(NCT00074412)
Timeframe: At Month 6

,
Interventionparticipants (Number)
# of HIV infections at 6 months# of Infants at risk for HIV infection at 6 months
Nevirapine8700
Placebo18699

Infant Survival Rates (Mortality Regardless of HIV Infection) in the Two Arms

(NCT00074412)
Timeframe: At Month 18

,
Interventionparticipants (Number)
# Infant Deaths at 18 months# Infants at risk of death at 18 months
Nevirapine26678
Placebo30684

Proportion of Infants Who Are Alive and HIV-uninfected in the Two Arms

(NCT00074412)
Timeframe: At Months 6 and 18

,
Interventionparticipants (Number)
Number of Infants Alive and HIV-free at 6 monthsNumber of Infants Alive and HIV-free at 18 months
Nevirapine689629
Placebo683616

Relative Rates of HIV Infection in the Two Arms

(NCT00074412)
Timeframe: At Month 18

,
Interventionparticipants (Number)
# of infants with HIV infection at 18 months# of infants @ risk for HIV infection at 18 months
Nevirapine16664
Placebo23663

Trials

7 trials available for nevirapine and Viremia

ArticleYear
Maternal HBV Viremia and Association With Adverse Infant Outcomes in Women Living With HIV and HBV.
    The Pediatric infectious disease journal, 2021, 02-01, Volume: 40, Issue:2

    Topics: Anti-HIV Agents; Birth Weight; Coinfection; Double-Blind Method; Female; Hepatitis B; Hepatitis B vi

2021
High rate of HIV resuppression after viral failure on first-line antiretroviral therapy in the absence of switch to second-line therapy.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2014, Volume: 58, Issue:7

    Topics: Anti-HIV Agents; Dideoxynucleosides; Drug Combinations; Humans; Lamivudine; Nevirapine; Viral Load;

2014
Effectiveness of option B highly active antiretroviral therapy (HAART) prevention of mother-to-child transmission (PMTCT) in pregnant HIV women.
    BMC research notes, 2014, Jan-21, Volume: 7

    Topics: Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4

2014
Reuse of nevirapine in exposed HIV-infected children after protease inhibitor-based viral suppression: a randomized controlled trial.
    JAMA, 2010, Sep-08, Volume: 304, Issue:10

    Topics: Anti-HIV Agents; Child, Preschool; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans;

2010
Reuse of nevirapine in exposed HIV-infected children after protease inhibitor-based viral suppression: a randomized controlled trial.
    JAMA, 2010, Sep-08, Volume: 304, Issue:10

    Topics: Anti-HIV Agents; Child, Preschool; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans;

2010
Reuse of nevirapine in exposed HIV-infected children after protease inhibitor-based viral suppression: a randomized controlled trial.
    JAMA, 2010, Sep-08, Volume: 304, Issue:10

    Topics: Anti-HIV Agents; Child, Preschool; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans;

2010
Reuse of nevirapine in exposed HIV-infected children after protease inhibitor-based viral suppression: a randomized controlled trial.
    JAMA, 2010, Sep-08, Volume: 304, Issue:10

    Topics: Anti-HIV Agents; Child, Preschool; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans;

2010
High frequency of rapid immunological progression in African infants infected in the era of perinatal HIV prophylaxis.
    AIDS (London, England), 2007, Jun-19, Volume: 21, Issue:10

    Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Disease Progression; Drug Administration Schedule; Drug Thera

2007
Pharmacokinetics, safety, and activity of nevirapine in human immunodeficiency virus type 1-infected children.
    The Journal of infectious diseases, 1996, Volume: 174, Issue:4

    Topics: Acquired Immunodeficiency Syndrome; Administration, Oral; Adolescent; Antiviral Agents; CD4 Lymphocy

1996
Pharmacokinetics, safety, and activity of nevirapine in human immunodeficiency virus type 1-infected children.
    The Journal of infectious diseases, 1996, Volume: 174, Issue:4

    Topics: Acquired Immunodeficiency Syndrome; Administration, Oral; Adolescent; Antiviral Agents; CD4 Lymphocy

1996
Pharmacokinetics, safety, and activity of nevirapine in human immunodeficiency virus type 1-infected children.
    The Journal of infectious diseases, 1996, Volume: 174, Issue:4

    Topics: Acquired Immunodeficiency Syndrome; Administration, Oral; Adolescent; Antiviral Agents; CD4 Lymphocy

1996
Pharmacokinetics, safety, and activity of nevirapine in human immunodeficiency virus type 1-infected children.
    The Journal of infectious diseases, 1996, Volume: 174, Issue:4

    Topics: Acquired Immunodeficiency Syndrome; Administration, Oral; Adolescent; Antiviral Agents; CD4 Lymphocy

1996
Higher rate of toxicity with no increased efficacy when hydroxyurea is added to a regimen of stavudine plus didanosine and nevirapine in primary HIV infection.
    Journal of acquired immune deficiency syndromes (1999), 2002, Apr-01, Volume: 29, Issue:4

    Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; Female; HIV Inf

2002

Other Studies

17 other studies available for nevirapine and Viremia

ArticleYear
Substitution of nevirapine or raltegravir for protease inhibitor vs. rosuvastatin treatment for the management of dyslipidaemia in HIV-infected patients on stable antiretroviral therapy (Nevrast study).
    Infectious diseases (London, England), 2017, Volume: 49, Issue:10

    Topics: Adult; Anti-HIV Agents; Anticholesteremic Agents; Antiretroviral Therapy, Highly Active; Cholesterol

2017
Evaluation of residual viremia and quantitation of soluble CD14 in a large cohort of HIV-infected adults on a long-term non-nucleoside reverse transcriptase inhibitor-based regimen.
    Journal of medical virology, 2013, Volume: 85, Issue:11

    Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cohort Studies; Cross-Sectional Studies; Cyclopropane

2013
Residual viremia in patients on antiretroviral therapy incorporating nevirapine is not associated with the gag-specific cellular immune response.
    Journal of medical virology, 2014, Volume: 86, Issue:6

    Topics: Adult; Aged; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Case-Control Studies; En

2014
The relation between efavirenz versus nevirapine and virologic failure in Johannesburg, South Africa.
    Journal of the International AIDS Society, 2014, Volume: 17

    Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Female; Follow-Up Studies;

2014
Effectiveness of a Treatment Switch to Nevirapine plus Tenofovir and Emtricitabine (or Lamivudine) in Adults with HIV-1 Suppressed Viremia.
    PloS one, 2015, Volume: 10, Issue:6

    Topics: Adult; Anti-Retroviral Agents; Drug Combinations; Emtricitabine; Female; HIV-1; Humans; Lamivudine;

2015
Effect of Lopinavir and Nevirapine Concentrations on Viral Outcomes in Protease Inhibitor-experienced HIV-infected Children.
    The Pediatric infectious disease journal, 2016, Volume: 35, Issue:12

    Topics: Child, Preschool; Drug Monitoring; HIV Infections; HIV Protease Inhibitors; Humans; Infant; Lopinavi

2016
Higher efficacy of nevirapine than efavirenz to achieve HIV-1 plasma viral load below 1 copy/ml.
    AIDS (London, England), 2011, Jan-28, Volume: 25, Issue:3

    Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes;

2011
Induction therapy with protease-inhibitors modifies the effect of nevirapine resistance on virologic response to nevirapine-based HAART in children.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2011, Feb-15, Volume: 52, Issue:4

    Topics: Antiretroviral Therapy, Highly Active; Child, Preschool; Drug Resistance, Viral; Female; Genotype; H

2011
Resolution of HCV infection in a HIV-infected patient under HAART after several hepatitis flare-ups.
    European journal of medical research, 2003, Nov-12, Volume: 8, Issue:11

    Topics: Acute Disease; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Hepatitis C, Chronic;

2003
In vivo dynamics of the 103N mutation following the withdrawal of non-nucleoside reverse transcriptase inhibitors in HIV-infected patients: preliminary results.
    The new microbiologica, 2004, Volume: 27, Issue:2 Suppl 1

    Topics: Alkynes; Amino Acid Substitution; Base Sequence; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes;

2004
HIV-1 intermittent viraemia in patients treated by non-nucleoside reverse transcriptase inhibitor-based regimen.
    AIDS (London, England), 2005, Jul-01, Volume: 19, Issue:10

    Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Female; HI

2005
Dynamics of 103K/N and 184M/V HIV-1 drug resistant populations: relative comparison in plasma virus RNA versus CD45RO+T cell proviral DNA.
    Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2007, Volume: 39, Issue:3

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; DNA, Viral; Drug Resistance, Viral; Drug Ther

2007
High turnover of HIV in blood revealed by new studies.
    Science (New York, N.Y.), 1995, Jan-13, Volume: 267, Issue:5195

    Topics: Antiviral Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; HIV; HIV Infections; HIV Proteas

1995
Comparison of virus burden in blood and sequential lymph node biopsy specimens from children infected with human immunodeficiency virus.
    The Journal of pediatrics, 1996, Volume: 129, Issue:3

    Topics: Antiviral Agents; Biopsy; CD4 Lymphocyte Count; Child; Child, Preschool; Didanosine; DNA, Viral; Dru

1996
Overshoot of HIV-1 viraemia after early discontinuation of antiretroviral treatment.
    AIDS (London, England), 1997, Volume: 11, Issue:11

    Topics: Anti-HIV Agents; CD4 Lymphocyte Count; HIV Core Protein p24; HIV Infections; HIV-1; Humans; Indinavi

1997
New information on HIV rapid turnover--what does it mean?
    AIDS treatment news, 1995, Jan-20, Issue:No 215

    Topics: Antiviral Agents; CD4 Lymphocyte Count; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Indina

1995
Experience of nevirapine use in a London cohort of HIV-infected pregnant women.
    HIV medicine, 2001, Volume: 2, Issue:2

    Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Female; HIV Infections; HIV-1; Humans;

2001